Nuvation Bio Announces $250M Convertible Notes Offering

Nuvation Bio has priced a $250 million convertible notes offering with an interest rate of 0.75%, maturing in 2032. The underwritten deal was upsized from the previously announced amount, signaling strong investor demand.

By Arundhati Sarkar, SA News Editor · Seeking Alpha · June 26, 2026, 05:38 UTC

Nuvation Bio Announces $250M Convertible Notes Offering

Tickers: $NUVB

Topics: capital raising convertible notes

Read the full article at Seeking Alpha

More World news

EY Report Outlines Three Fundamental Shifts Required for Future-Ready Health Systems by 2040 PR Newswire · November 12, 2026, 15:24 UTC
ProLift Garage Doors Expands Franchise Services and Support Initiatives PR Newswire · November 12, 2026, 15:24 UTC
Pomerantz Law Firm Investigates Cerebras Systems Inc. Over Potential Securities Fraud PR Newswire · November 12, 2026, 15:25 UTC
CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC